Drugmaker Novartis AG is reportedly in talks with U.S. payers over possible price discounts for Zolgensma, its new gene therapy for spinal muscular atrophy (SMA).
According to a Reuters report, the discounts would not be without certain conditions. Dave Lennon, chief of Novartis’ AveXis, tells Reuters Novartis wants payers to ensure its therapy is used for patients identified with SMA.
Lennon also said Novartis is working to solicit widespread screening on newborns to identify the disease early and secure quick authorization for the therapy.
“We are very much interested in making sure that payers [support] newborn screening, that they establish fast turnaround on coverage decisions, and that they have specific policies that cover gene therapy for SMA,” Lennon told Reuters.
To read the full report on Reuters, click here.